Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

This study reports that topical ruxolitinib failed to induce hair growth in a 66-year-old patient with alopecia areata, highlighting the need to explore factors affecting treatment response and compare topical vs oral administration outcomes.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

This review discusses central centrifugal cicatricial alopecia in adult women of African descent and reports no clinical results; the authors highlight traditional treatments and their impact on quality of life.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This study reported that topical drugs regrew hair in mice.

This study found that topical curcumin can initiate hair growth in mice by acting as a JAK inhibitor but could not fully reverse alopecia areata, likely due to insufficient penetration to deeper skin layers.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.

Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.

This review discusses the unclear etiology and potential contributing factors of frontal fibrosing alopecia and reports no new clinical findings.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

This research focuses on alopecia areata, highlighting the psychological impact, especially of its variant alopecia areata incognita, and provides diagnostic and treatment tips, but does not report specific results.

This review highlights that a comprehensive approach combining pharmacological, immunomodulatory, and regenerative interventions, including phototherapy enhanced with topical treatments and JAK inhibitors, appears effective and promising in the management of vitiligo by addressing its autoimmune and melanocyte-loss aspects.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.